FOR IMMEDIATE RELEASE
 February 14, 2005
 Burlington, Ontario

 THE JENEX CORPORATION ("Jenex" or the "Corporation") (TSX Venture
Exchange - JEN), The Corporation reports it has received correspondence from the United States Securities and Exchange Commission (“SEC”) in connection with its submission of a Form 20-F Registration Statement to become fully reporting in the United States. In preparing its response to the SEC review, the Corporation has amended some disclosures and provided further disclosures where appropriate to their previously filed July 31, 2004 audited fiscal year end statements and first quarter financial statements ending October 31,2004.

Donald Felice, V.P. and CFO of Jenex states, “The figures in the balance sheets and income statements of the amended financial statements remain consistent with our previously filed financial statements. The amended financial statements enhance the Corporation’s disclosures and improve compliance with the rules and regulations of the SEC and with U.S. generally accepted accounting principles (U.S. GAAP). 

Michael Jenkins, President and CEO of Jenex states, ”Our pursuit of a listing in the US is an important step towards advancing investor visibility as we prepare to launch our Intercept CS product, for the PREVENTION of cold sores. A US listing will provide increased awareness and accessibility for US and International investors. Concurrently, we continue to implement our worldwide licensing strategy for Therapik and expand our licensed markets. We are currently pursuing opportunities in Europe, South America and the USA.”

 About The Jenex Corporation
 Headquartered in Burlington, Ontario, the Corporation owns a patented
Thermal Therapy technology.  Patents in the United States, Canada,
Australia, and Europe protect the technology. The first device developed
from this technology is the Therapik® product, for insect stings and bites.
The second device, interceptCS is the first product proven and approved to
prevent cold sores.  Jenex has been approved to market interceptCS in Canada
with its approved claim, "For prevention and relief of the symptoms of
herpes labialis (cold sores), such as blistering, lesions, inflammation, and
discomfort. Also helps alleviate the embarrassment that is typically
associated with herpes labialis (cold sore) outbreaks". The Corporation is
preparing for the launch of interceptCS in the Canadian market in second half 2005. Current medical research indicates that 20 to 40% of the population experience recurrent cold sore outbreaks. More information about the Corporation can be found at www.jenexcorp.com .

 Direct Inquiries:
 Michael Jenkins,
 The Jenex Corporation
 E-Mail: jenex@jenexcorp.com
 Tel:  (416) 632-3830    Fax:  (416) 632-3774

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release.
Certain information included in this press release is forward-looking and is
subject to important risks and uncertainties.  The results or events
predicted in these statements may differ materially from actual results or
events.